

# BEST AVAILABLE COPY

10/8/4, 1998  
updated search  
L/cook 6/5/06

d his

(FILE 'HOME' ENTERED AT 10:00:26 ON 05 JUN 2006)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 10:00:39 ON 05  
JUN 2006

L1 18031 S PHOSPHOCHOLINE?  
L2 14387 S PHOSPHORYLCHOLINE?  
L3 2628 S L1 AND (PLATELET ACTIVATING FACTOR)  
L4 1252 S L2 AND (PLATELET ACTIVATING FACTOR)  
L5 89 S L3 AND ANTIBOD?  
L6 56 S L4 AND ANTIBOD?  
L7 34 DUPLICATE REMOVE L5 (55 DUPLICATES REMOVED)  
L8 32 DUPLICATE REMOVE L6 (24 DUPLICATES REMOVED)  
L9 22 S L7 AND PD<1998  
L10 20 S L8 AND PD<1998  
L11 0 S L9 AND L10  
L12 3076 S (PLATELET ACTIVATING FACTOR) AND ANTIBOD?  
L13 56 S L12 AND L2

=>

d his

(FILE 'HOME' ENTERED AT 10:00:26 ON 05 JUN 2006)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 10:00:39 ON 05  
JUN 2006

L1 18031 S PHOSPHOCHOLINE?  
L2 14387 S PHOSPHORYLCHOLINE?  
L3 2628 S L1 AND (PLATELET ACTIVATING FACTOR)  
L4 1252 S L2 AND (PLATELET ACTIVATING FACTOR)  
L5 89 S L3 AND ANTIBOD?  
L6 56 S L4 AND ANTIBOD?  
L7 34 DUPLICATE REMOVE L5 (55 DUPLICATES REMOVED)  
L8 32 DUPLICATE REMOVE L6 (24 DUPLICATES REMOVED)  
L9 22 S L7 AND PD<1998  
L10 20 S L8 AND PD<1998  
L11 0 S L9 AND L10  
L12 3076 S (PLATELET ACTIVATING FACTOR) AND ANTIBOD?  
L13 56 S L12 AND L2

=>

ANSWER 18 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1990:589360 CAPLUS

DN 113:189360

ED Entered STN: 23 Nov 1990

TI **Antibodies to platelet-activating factor**

AU Karasawa, Ken; Satoh, Noriko; Hongo, Toshio; Setaka, Morio; Mowri, Hiroomi; Takano, Tatsuya; Hashimoto, Shunichi; Ikegami, Shiro; Fujita, Kagari; et al.

CS Fac. Pharm. Sci., Teikyo Univ., Sagamiko, 199-01, Japan

SO Trends Pharmacol. Res. Platelet Act. Factor (PAF) Jpn., Proc. Symp. Probl. PAF, 11th (1988), Meeting Date 1987, 138-46. Editor(s): Ogura, Yasumi; Kisara, Kensaku. Publisher: Ishiyaku EuroAmerica, Tokyo, Japan. CODEN: 56ULA2

DT Conference

LA English

CC 15-3 (Immunochemistry)

AB Specific **antibodies to platelet-activating factor (PAF)** were prepared by immunizing rabbits with a hapten-bovine serum albumin (BSA) conjugate. As hapten a synthetic PAF derivative was used which is resistant to enzymic inactivation by plasma or tissues and which can bind to BSA through covalent bonding at the  $\omega$ -position of the alkyl side chain. **Antibody** activity was determined by ELISA. Anti-PAF IgG reacted strongly with PAF. By means of the ELISA inhibition assay, **antibodies** did not cross-react with **phosphocholine** glycerophosphocholine, dilaurylglycerophosphocholine, or PAF analogs which have ethanolamine-type polar head groups instead of choline groups. The monoclonal **antibodies** were also produced in Balb/c mouse using the same immunizing method. When PAF was incubated with monoclonal **antibodies** and protein A Sepharose, supernatant did not cause rabbit platelet aggregation. The specificity and sensitivity of the mouse monoclonal **antibodies** were compared with those of rabbit polyclonal **antibodies**.

ST **platelet activating factor antibody**

IT Immunoglobulins

RL: FORM (Formation, nonpreparative)  
(G, formation of, to **platelet-activating factor**, synthetic hapten induction of)

IT **Antibodies**

RL: FORM (Formation, nonpreparative)  
(monoclonal, formation of, to **platelet-activating factor**, synthetic hapten induction of)

IT 65154-06-5, Blood **platelet-activating factor**

RL: BIOL (Biological study)  
(**antibodies** to, synthetic analog hapten in formation of)

IT 130126-32-8

RL: BIOL (Biological study)  
(as hapten for **antibody** formation to **platelet-activating factor**)

AN 1990:589360 CAPLUS

DN 113:189360

ED Entered STN: 23 Nov 1990

TI **Antibodies to platelet-activating factor**

AU Karasawa, Ken; Satoh, Noriko; Hongo, Toshio; Setaka, Morio; Mowri, Hiroomi; Takano, Tatsuya; Hashimoto, Shunichi; Ikegami, Shiro; Fujita, Kagari; et al.

CS Fac. Pharm. Sci., Teikyo Univ., Sagamiko, 199-01, Japan

SO Trends Pharmacol. Res. Platelet Act. Factor (PAF) Jpn., Proc. Symp. Probl. PAF, 11th (1988), Meeting Date 1987, 138-46. Editor(s): Ogura, Yasumi; Kisara, Kensaku. Publisher: Ishiyaku EuroAmerica, Tokyo, Japan. CODEN: 56ULA2

DT Conference

LA English

CC 15-3 (Immunochemistry)

AB **Specific antibodies to platelet-activating factor (PAF)** were prepared by immunizing rabbits with a hapten-bovine serum albumin (BSA) conjugate. As hapten a synthetic PAF derivative was used which is resistant to enzymic inactivation by plasma or tissues and which can bind to BSA through covalent bonding at the  $\omega$ -position of the alkyl side chain. **Antibody** activity was determined by ELISA. Anti-PAF IgG reacted strongly with PAF. By means of the ELISA inhibition assay, **antibodies** did not cross-react with **phosphocholine** glycerophosphocholine, dilaurylglycerophosphocholine, or PAF analogs which have ethanolamine-type polar head groups instead of choline groups. The monoclonal **antibodies** were also produced in Balb/c mouse using the same immunizing method. When PAF was incubated with monoclonal **antibodies** and protein A Sepharose, supernatant did not cause rabbit platelet aggregation. The specificity and sensitivity of the mouse monoclonal **antibodies** were compared with those of rabbit polyclonal **antibodies**.

ST **platelet activating factor antibody**

IT Immunoglobulins

RL: FORM (Formation, nonpreparative)  
(G, formation of, to **platelet-activating factor**, synthetic hapten induction of)

IT **Antibodies**

RL: FORM (Formation, nonpreparative)  
(monoclonal, formation of, to **platelet-activating factor**, synthetic hapten induction of)

IT 65154-06-5, Blood **platelet-activating factor**

RL: BIOL (Biological study)  
(**antibodies** to, synthetic analog hapten in formation of)

IT 130126-32-8

RL: BIOL (Biological study)  
(as hapten for **antibody** formation to **platelet-activating factor**)

ANSWER 7 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:91686 CAPLUS

DN 110:91686

ED Entered STN: 17 Mar 1989

TI Antigenic analogs of **platelet-activating factor** (PAF), production of the analogs and **antibodies** to them, and PAF immunoassays

IN Baldo, Brian Angelo; Redmond, John William

PA University of Sydney, Australia; Macquarie University; Royal North Shore Hospital

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07F009-10

ICS G01N033-92; C07K015-12

CC 9-10 (Biochemical Methods)

Section cross-reference(s): 7, 23, 29

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8705904	A1	19871008	WO 1987-AU84	19870324 <--
	W: AU, JP, KR, US				
	RW: DE, FR, GB, IT				
	AU 8772097	A1	19871020	AU 1987-72097	19870324 <--
	AU 607698	B2	19910314		
	EP 299965	A1	19890125	EP 1987-902318	19870324 <--
	R: DE, FR, GB, IT				
	JP 01502584	T2	19890907	JP 1987-502157	19870324 <--
	IL 82057	A1	19941111	IL 1987-82057	19870331 <--
	US 5061626	A	19911029	US 1987-156923	19871124 <--
PRAI	AU 1986-5175	A	19860324		
	WO 1987-AU84	A	19870324		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 8705904	ICM	C07F009-10
	ICS	G01N033-92; C07K015-12
	IPCI	C07F0009-10 [ICM,4]; C07F0009-00 [ICM,4,C*]; G01N0033-92 [ICS,4]; C07K0015-12 [ICS,4]
	IPCR	A61K0039-00 [N,A]; A61K0039-00 [N,C*]; C07F0009-00 [I,C*]; C07F0009-10 [I,A]; C07K0001-00 [I,C*]; C07K0001-107 [I,A]; C07K0016-18 [I,A]; C07K0016-18 [I,C*]; G01N0033-86 [I,A]; G01N0033-86 [I,C*]
AU 8772097	IPCI	C07F0009-10 [ICM,4]; C07F0009-00 [ICM,4,C*]; G01N0033-92 [ICS,4]; C07K0015-12 [ICS,4]
	IPCR	A61K0039-00 [N,A]; A61K0039-00 [N,C*]; C07F0009-00 [I,C*]; C07F0009-10 [I,A]; C07K0001-00 [I,C*]; C07K0001-107 [I,A]; C07K0016-18 [I,A]; C07K0016-18 [I,C*]; G01N0033-86 [I,A]; G01N0033-86 [I,C*]
EP 299965	IPCI	C07F0009-10 [ICM,4]; C07F0009-00 [ICM,4,C*]; G01N0033-92 [ICS,4]; C07K0015-12 [ICS,4]
	IPCR	A61K0039-00 [N,A]; A61K0039-00 [N,C*]; C07F0009-00 [I,C*]; C07F0009-10 [I,A]; C07K0001-00 [I,C*]; C07K0001-107 [I,A]; C07K0016-18 [I,A]; C07K0016-18 [I,C*]; G01N0033-86 [I,A]; G01N0033-86 [I,C*]
JP 01502584	IPCI	C07F0009-10 [ICM,4]; C07F0009-00 [ICM,4,C*]; A61K0039-395 [ICS,4]; C07K0003-08 [ICS,4]; C07K0015-12 [ICS,4]; G01N0033-53 [ICS,4]
IL 82057	IPCI	C07K0015-06 [ICM,5]; C07K0007-00 [ICS,5]; C07H0005-06 [ICS,5]; C07H0005-00 [ICS,5,C*]; C07F0009-10 [ICS,5]; C07F0009-00 [ICS,5,C*]; C08B0037-00 [ICS,5]; G01N0033-53 [ICS,5]
US 5061626	IPCI	C12N0011-00

IPCR A61K0039-00 [N,A]; A61K0039-00 [N,C\*]; C07F0009-00 [I,C\*]; C07F0009-10 [I,A]; C07K0001-00 [I,C\*]; C07K0001-107 [I,A]; C07K0016-18 [I,A]; C07K0016-18 [I,C\*]; G01N0033-86 [I,A]; G01N0033-86 [I,C\*]  
 NCL 435/174.000; 435/192.000; 435/199.000; 435/207.000; 436/545.000; 436/546.000; 530/345.000; 530/402.000; 530/403.000; 530/404.000; 530/406.000; 530/408.000; 530/409.000; 530/410.000; 554/080.000; 558/169.000; 558/172.000

OS MARPAT 110:91686  
 GI



AB PAF analogs I [R1 = C2-25 alkylene or alkenylene linking group substituted by radioactive I and X = H; or R1 = C2-25 alkylene, alkenylene, alkynylene, optionally 3H- or radioactive I-substituted, and X = CHO, di(C1-6 alkoxy)methyl, CO<sub>2</sub>H, NCO, OH, SH, N-(C1-6 alkyl)amino, N,N-di(C1-6 alkyl)amino, AB; A = linking group (NR<sub>6</sub>, CO<sub>2</sub>, O<sub>2</sub>C, CONR<sub>6</sub>, NR<sub>6</sub>CO, NHCSNH, SS; R<sub>6</sub> = H, C1-6 alkyl); B = protein, peptide, carbohydrate, lipid of ≥2000 mol. weight, label; R<sub>2</sub>-R<sub>5</sub> = C1-6 alkyl] are prepared and are useful in production of anti-PAF **antibodies** or as reagents in PAF immunoassays. 2-O-Acetyl-1-O-(6'-oxohexyl)-sn-glycerol-3-phosphorylcholine [prepared from cyclohexanone and HC(OMe)<sub>3</sub> in 8 steps] was conjugated to methylated bovine serum albumin. The conjugate was used to prepare rabbit anti-PAF serum which was used in an assay for PAF.

ST **platelet activating factor analog**  
**antibody** immunoassay; acetyloxohexylglycerylphosphorylcholine albumin conjugate; **phosphorylcholine** acetyloxohexylglyceryl albumin conjugate

IT Veterinary medicine  
 (blood **platelet-activating factor** determination  
 by immunoassay in relation to)

IT Blood analysis  
 Body fluid  
 (blood **platelet-activating factor** determination  
 in, by immunoassay, antigenic and labeled analogs for)

IT Detergents  
 Lecithins  
 Ethers, uses and miscellaneous  
 Polyoxyalkylenes, uses and miscellaneous  
 RL: ANST (Analytical study)  
 (in blood **platelet-activating factor**  
 determination in body fluid by immunoassay)


IT **Antibodies**  
 RL: ANST (Analytical study)  
 (to blood **platelet-activating factor**  
 analogs)

IT Ethers, biological studies  
 RL: USES (Uses)  
 (Ph, in blood **platelet-activating factor**  
 determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, compounds

IPCR A61K0039-00 [N,A]; A61K0039-00 [N,C\*]; C07F0009-00 [I,C\*]; C07F0009-10 [I,A]; C07K0001-00 [I,C\*]; C07K0001-107 [I,A]; C07K0016-18 [I,A]; C07K0016-18 [I,C\*]; G01N0033-86 [I,A]; G01N0033-86 [I,C\*]  
 NCL 435/174.000; 435/192.000; 435/199.000; 435/207.000; 436/545.000; 436/546.000; 530/345.000; 530/402.000; 530/403.000; 530/404.000; 530/406.000; 530/408.000; 530/409.000; 530/410.000; 554/080.000; 558/169.000; 558/172.000

OS MARPAT 110:91686  
 GI



AB PAF analogs I [R1 = C2-25 alkylene or alkenylene linking group substituted by radioactive I and X = H; or R1 = C2-25 alkylene, alkenylene, alkynylene, optionally 3H- or radioactive I-substituted, and X = CHO, di(C1-6 alkoxy)methyl, CO2H, NCO, OH, SH, N-(C1-6 alkyl)amino, N,N-di(C1-6 alkyl)amino, AB; A = linking group (NR6, CO2, O2C, CONR6, NR6CO, NHCSNH, SS; R6 = H, C1-6 alkyl); B = protein, peptide, carbohydrate, lipid of  $\geq 2000$  mol. weight, label; R2-R5 = C1-6 alkyl] are prepared and are useful in production of anti-PAF **antibodies** or as reagents in PAF immunoassays. 2-O-Acetyl-1-O-(6'-oxohexyl)-sn-glycerol-3-phosphorylcholine [prepared from cyclohexanone and HC(OMe)3 in 8 steps] was conjugated to methylated bovine serum albumin. The conjugate was used to prepare rabbit anti-PAF serum which was used in an assay for PAF.

ST **platelet activating factor analog**  
**antibody** immunoassay; acetyloxohexylglycerylphosphorylcholine albumin conjugate; **phosphorylcholine** acetyloxohexylglyceryl albumin conjugate

IT Veterinary medicine  
 (blood **platelet-activating factor** determination by immunoassay in relation to)  
 IT Blood analysis  
 Body fluid  
 (blood **platelet-activating factor** determination in, by immunoassay, antigenic and labeled analogs for)

IT Detergents  
 Lecithins  
 Ethers, uses and miscellaneous  
 Polyoxyalkylenes, uses and miscellaneous  
 RL: ANST (Analytical study)  
 (in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT **Antibodies**  
 RL: ANST (Analytical study)  
 (to blood **platelet-activating factor** analogs)

IT Ethers, biological studies  
 RL: USES (Uses)  
 (Ph, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, compounds

RL: ANST (Analytical study)  
 (acetals, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, esters  
 RL: ANST (Analytical study)  
 (alditols, anhydro, esters, with fatty acids, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Castor oil  
 RL: ANST (Analytical study)  
 (alkoxylated, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Albumins, compounds  
 Carbohydrates and Sugars, compounds  
 Lipids, compounds  
 Peptides, compounds  
 Proteins, specific or class  
 RL: ANST (Analytical study)  
 (conjugates, with glycerylphosphorylcholine derivative, as antigenic blood **platelet-activating factor** analogs)

IT Enzymes  
 RL: ANST (Analytical study)  
 (conjugates, with glycerylphosphorylcholine derivs., as labeled blood **platelet-activating factor** analogs)

IT Fatty acids, esters  
 RL: ANST (Analytical study)  
 (esters, with hexitol anhydrides, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, esters  
 RL: ANST (Analytical study)  
 (hexitols, anhydro, esters, with fatty acids, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Alcohols, compounds  
 RL: ANST (Analytical study)  
 (long-chain, alkoxylated, acetals, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT **Antibodies**  
 RL: ANST (Analytical study)  
 (monoclonal, to blood **platelet-activating factor** analogs)

IT Detergents  
 (nonionic, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT 25104-18-1D, Polylysine, glycerylphosphorylcholine derivative conjugates  
 38000-06-5D, Polylysine, glycerylphosphorylcholine derivative conjugates  
 119142-22-2D, albumin and polylysine conjugates  
 RL: ANST (Analytical study)  
 (as antigenic blood **platelet-activating factor** analogs)

IT 9005-64-5, Tween 20  
 RL: ANST (Analytical study)  
 (blood **platelet-activating factor** acetylhydrolase inactivation by, blood **platelet-activating factor** immunoassay in relation to)

IT 51-45-6D, 1H-Imidazole-4-ethanamine, iodine-125-labeled 51-67-2D, iodine-125-labeled 1080-06-4D, iodine-125-labeled  
 RL: ANST (Analytical study)  
 (blood **platelet-activating factor** analogs labeled with, for immunoassay)

IT 65154-06-5, Blood **platelet-activating factor**  
 RL: ANT (Analyte); ANST (Analytical study)  
 (determination of, by immunoassay, antigenic and labeled analogs for)



RL: ANST (Analytical study)  
 (acetals, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, esters  
 RL: ANST (Analytical study)  
 (alditols, anhydro, esters, with fatty acids, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Castor oil  
 RL: ANST (Analytical study)  
 (alkoxylated, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Albumins, compounds  
 Carbohydrates and Sugars, compounds  
 Lipids, compounds  
 Peptides, compounds  
 Proteins, specific or class  
 RL: ANST (Analytical study)  
 (conjugates, with glycerylphosphorylcholine derivative, as antigenic blood **platelet-activating factor** analogs)

IT Enzymes  
 RL: ANST (Analytical study)  
 (conjugates, with glycerylphosphorylcholine derivs., as labeled blood **platelet-activating factor** analogs)

IT Fatty acids, esters  
 RL: ANST (Analytical study)  
 (esters, with hexitol anhydrides, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, esters  
 RL: ANST (Analytical study)  
 (hexitols, anhydro, esters, with fatty acids, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Alcohols, compounds  
 RL: ANST (Analytical study)  
 (long-chain, alkoxylated, acetals, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT **Antibodies**  
 RL: ANST (Analytical study)  
 (monoclonal, to blood **platelet-activating factor** analogs)

IT Detergents  
 (nonionic, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT 25104-18-1D, Polylysine, glycerylphosphorylcholine derivative conjugates  
 38000-06-5D, Polylysine, glycerylphosphorylcholine derivative conjugates  
 119142-22-2D, albumin and polylysine conjugates  
 RL: ANST (Analytical study)  
 (as antigenic blood **platelet-activating factor** analogs)

IT 9005-64-5, Tween 20  
 RL: ANST (Analytical study)  
 (blood **platelet-activating factor** acetylhydrolase inactivation by, blood **platelet-activating factor** immunoassay in relation to)

IT 51-45-6D, 1H-Imidazole-4-ethanamine, iodine-125-labeled 51-67-2D, iodine-125-labeled 1080-06-4D, iodine-125-labeled  
 RL: ANST (Analytical study)  
 (blood **platelet-activating factor** analogs labeled with, for immunoassay)

IT 65154-06-5, Blood **platelet-activating factor**  
 RL: ANT (Analyte); ANST (Analytical study)  
 (determination of, by immunoassay, antigenic and labeled analogs for)

IT 108-95-2D, Phenol, alkyl ethers  
 RL: ANST (Analytical study)  
 (in blood **platelet-activating factor**  
 determination in body fluid by immunoassay)

IT 76901-00-3, **Platelet activating factor**  
 acetylhydrolase  
 RL: ANST (Analytical study)  
 (inactivation of, by Tween 20, blood **platelet-**  
**activating factor** immunoassay in relation to)

IT 931-56-6P, 1-Methoxycyclohexane 933-40-4P, 1,1-Dimethoxycyclohexane  
 18751-83-2P, 6,6-Dimethoxyhexan-1-ol 25176-55-0P, Methyl-6,6-  
 dimethoxyhexanoate 119142-18-6P 119142-19-7P 119142-20-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and reaction of, in preparation of blood **platelet-**  
**activating factor** analogs)

IT 119142-21-1DP, methylated albumin conjugates  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as immunogen for blood **platelet-**  
**activating factor** immunoassay)

IT 108-94-1, Cyclohexanone, reactions 149-73-5, Trimethylorthoformate  
 119142-17-5, (R)-1-(Benzyloxy)-2,3-epoxypropane  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, in preparation of blood **platelet-activating**  
**factor** analogs)

IT 108-95-2D, Phenol, alkyl ethers  
 RL: ANST (Analytical study)  
 (in blood **platelet-activating factor**  
 determination in body fluid by immunoassay)

IT 76901-00-3, **Platelet activating factor**  
 acetylhydrolase  
 RL: ANST (Analytical study)  
 (inactivation of, by Tween 20, blood **platelet-**  
**activating factor** immunoassay in relation to)

IT 931-56-6P, 1-Methoxycyclohexane 933-40-4P, 1,1-Dimethoxycyclohexane  
 18751-83-2P, 6,6-Dimethoxyhexan-1-ol 25176-55-0P, Methyl-6,6-  
 dimethoxyhexanoate 119142-18-6P 119142-19-7P 119142-20-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and reaction of, in preparation of blood **platelet-**  
**activating factor** analogs)

IT 119142-21-1DP, methylated albumin conjugates  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as immunogen for blood **platelet-**  
**activating factor** immunoassay)

IT 108-94-1, Cyclohexanone, reactions 149-73-5, Trimethylorthoformate  
 119142-17-5, (R)-1-(Benzyloxy)-2,3-epoxypropane  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, in preparation of blood **platelet-activating**  
**factor** analogs)